Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.72 |
| ▸ | MC4R | P32245 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800706 | 0.98 | CCR3 (0.70) | CCR3MC4RSIGMAR1KCNH2LMNA | |
| SCHEMBL12040820 | 0.98 | CCR3 (0.70) | CCR3MC4RSIGMAR1KCNH2LMNA | |
| SCHEMBL8723260 | 0.98 | CCR3 (0.70) | CCR3MC4RSIGMAR1KCNH2LMNA | |
| SCHEMBL6740759 | 0.95 | CCR3 (0.69) | CCR3MC4RSIGMAR1LMNAPOLB | |
| SCHEMBL19170201 | 0.95 | CCR3 (0.69) | CCR3MC4RSIGMAR1LMNAPOLB | |
| SCHEMBL13632432 | 0.95 | CCR3 (0.69) | CCR3MC4RSIGMAR1LMNAPOLB | |
| SCHEMBL12040822 | 0.94 | CCR3 (0.64) | CCR3MC4RSIGMAR1KCNH2LMNA | |
| SCHEMBL6657455 | 0.91 | CCR3 (0.85) | CCR3MC4RSIGMAR1LMNAPOLB | |
| SCHEMBL6657649 | 0.89 | CCR3 (0.82) | CCR3MC4RSIGMAR1LMNAPOLB | |
| SCHEMBL6744977 | 0.87 | SIGMAR1 (0.72) | CCR3MC4RSIGMAR1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101787002-B | 1-mustard acyl-4-benzylpiperazine derivative, preparation method thereof and application of anti-free radical or anti-inflammatory activity | SHANTOU UNIVERSITY MEDICAL COLLEGE (CN) | 2011-12-07 | — | — | CN | claimed |
| CN-101787002-A | 1-mustard acyl-4-benzylpiperazine derivative, preparation method thereof and application of anti-free radical or anti-inflammatory activity | MEDICAL COLLEGE OF SHANTOU UNI | 2010-07-28 | — | — | CN | claimed |
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-9993516-B2 | Treatment of left ventricular non-compaction and dilated cardiomyopathy by inhibiting melanocortin receptor four | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160296587-A1 | THERAPIES FOR LEFT VENTRICULAR NON-COMPACTION AND DILATED CARDIOMYOPATHY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015077334-A2 | THERAPIES FOR LEFT VENTRICULAR NON-COMPACTION AND DILATED CARDIOMYOPATHY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015031381-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C | ENANTA PHARMACEUTICALS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| CN-101787002-B | 1-mustard acyl-4-benzylpiperazine derivative, preparation method thereof and application of anti-free radical or anti-inflammatory activity | SHANTOU UNIVERSITY MEDICAL COLLEGE (CN) | 2011-12-07 | — | — | CN | disclosed |
| CN-101787002-B | 1-mustard acyl-4-benzylpiperazine derivative, preparation method thereof and application of anti-free radical or anti-inflammatory activity | SHANTOU UNIVERSITY MEDICAL COLLEGE (CN) | 2011-12-07 | — | — | CN | disclosed |
| CN-101787002-B | 1-mustard acyl-4-benzylpiperazine derivative, preparation method thereof and application of anti-free radical or anti-inflammatory activity | SHANTOU UNIVERSITY MEDICAL COLLEGE (CN) | 2011-12-07 | — | — | CN | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-6455528-B1 | TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| EP-1118612-A1 | Piperazine derivatives possesing nootropic activity | Universita Degli Studi di Firenze (IT) | 2001-07-25 | — | — | EP | disclosed |
| EP-0691962-B1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AG (DE) | 2000-09-13 | — | — | EP | disclosed |
| EP-1029851-A1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-08-23 | — | — | EP | disclosed |
| US-5622953-A | DRUG RESISTANT TO ANTICANCER CHEMOTHERAPEUTIC DRUG | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| WO-1994022842-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
| US-4950657-A | SYSTEMIC PESTICIDES, NEMATOCIDES, LOW MAMMALIAN AND FISH TOXICITY | THE DOW CHEMICAL COMPANY (US) | 1990-08-21 | — | — | US | disclosed |
| US-4374990-A | ANTIDEPRESSANTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-22 | — | — | US | disclosed |
| US-4115569-A | PARASITICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | CCR3 2505/4885MC4R 3320/4885SIGMAR1 1733/4885 |
| US-20160296587-A1 | THERAPIES FOR LEFT VENTRICULAR NON-COMPACTION AND DILATED CARDIOMYOPATHY | TNNI3, TNNT2, TNNC1 | CCR3 4148/4885MC4R 4183/4885SIGMAR1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.